Who
Jason Haas
Director
Company insider
Files Form 4 as: Director, Ligand Pharmaceuticals; Chief Financial Officer, Odyssey Therapeutics; Chief Financial Officer, Syros Pharmaceuticals.
In numbers
- Trades disclosed
- 56
- Buys
- 4
- Sells
- 3
- Bought
- $201K
- Sold
- $7.5M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 12 Oct 2021
- Last trade
- 12 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $316K6,138 at $51.56 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.1M7,138 at $292.81 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,138 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,138 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $316K6,138 at $51.56 | filing |
| 12 Aug 2026filed 14 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.1M7,138 at $292.81 | filing |
| 12 Jun 2026filed 15 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $155K3,000 at $51.56 | filing |
| 12 Jun 2026filed 15 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $52K1,000 at $51.56 | filing |
| 12 Jun 2026filed 15 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $765K3,000 at $255.01 | filing |
| 12 Jun 2026filed 15 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $886K3,461 at $256.08 | filing |
| 12 Jun 2026filed 15 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $155K3,000 at $51.56 | filing |
| 12 Jun 2026filed 15 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $52K1,000 at $51.56 | filing |
| 12 Jun 2026filed 15 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $765K3,000 at $255.01 | filing |
| 12 Jun 2026filed 15 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $886K3,461 at $256.08 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —836 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,938 at $0.00 | filing |
News
Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Ligand Pharmaceuticals (NASDAQ:LGND)LGND · tickerreport.com · 23 Oct 2026Odyssey Therapeutics Announces Encouraging Phase 2a Ulcerative Colitis ResultsODTX · rttnews.com · 20 Oct 2026
0 headlines in the last 90 days name Jason Haas; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.